If you can’t build the next Ozempic, buy it: Where M&A in the obesity drug space might be heading

If you can't build the next Ozempic, buy it: Where M&A in the obesity drug space might be heading

Investors are considering when and where the next big obesity drug deal will happen. Currently, Novo Nordisk and Eli Lilly have complete control of the growing obesity drug market. But …

Read more